Matinas BioPharma Stock Price, News & Analysis (NYSEAMERICAN:MTNB)

$1.19 -0.01 (-0.83 %)
(As of 01/19/2018 03:46 PM ET)
Previous Close$1.20
Today's Range$1.15 - $1.20
52-Week Range$1.01 - $3.99
Volume135,200 shs
Average Volume119,533 shs
Market Capitalization$118.05 million
P/E Ratio-3.22
Dividend YieldN/A
Beta0.69

About Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma logoMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:MTNB
CUSIPN/A
Phone+1-908-4431860

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-3.21621621621622
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.37)
Net IncomeN/A
Net Margins-7,558.92%
Return on Equity-195.09%
Return on Assets-79.34%

Miscellaneous

EmployeesN/A
Outstanding Shares92,950,000

Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) issued its quarterly earnings data on Wednesday, November, 15th. The company reported ($0.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.01. The business earned $0.05 million during the quarter, compared to analysts' expectations of $0.05 million. Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%. View Matinas BioPharma's Earnings History.

When will Matinas BioPharma make its next earnings announcement?

Matinas BioPharma is scheduled to release their next quarterly earnings announcement on Monday, April, 2nd 2018. View Earnings Estimates for Matinas BioPharma.

Where is Matinas BioPharma's stock going? Where will Matinas BioPharma's stock price be in 2018?

3 brokers have issued twelve-month price objectives for Matinas BioPharma's stock. Their forecasts range from $6.00 to $9.00. On average, they expect Matinas BioPharma's stock price to reach $7.67 in the next twelve months. View Analyst Ratings for Matinas BioPharma.

What are Wall Street analysts saying about Matinas BioPharma stock?

Here are some recent quotes from research analysts about Matinas BioPharma stock:

  • 1. Maxim Group analysts commented, "Summary Matinas stock is down sharply today on news that MAT2203’s efficacy in VVC (vulvovaginal candidiasis) fell well below expectations both internal and external, but wait a second…Was it ever supposed to compare?." (6/26/2017)
  • 2. Aegis analysts commented, "Matinas reported the results of the Phase I study testing safety, tolerability and pharmacokinetics of MAT2501, its cochleated version of amikacin. This announcement meets the endpoints and time frame we had expected. Separately, we have received inquiries regarding comments posted to a financial website to which we attribute the recent volatility in the stock. We believe these comments are based on incorrect information, and reiterate our Buy rating on the stock." (3/28/2017)

Are investors shorting Matinas BioPharma?

Matinas BioPharma saw a decline in short interest in December. As of December 29th, there was short interest totalling 1,464,128 shares, a decline of 15.0% from the December 15th total of 1,723,304 shares. Based on an average trading volume of 238,293 shares, the days-to-cover ratio is presently 6.1 days. Approximately 2.0% of the company's shares are sold short.

Who are some of Matinas BioPharma's key competitors?

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the folowing people:

  • Jerome D. Jabbour J.D., President (Age 42)
  • Roelof Rongen, Chief Executive Officer, Director (Age 51)
  • Gary Gaglione CPA, Vice President of Finance and Accounting and Acting Chief Financial Officer (Age 64)
  • Douglas F. Kling, Senior Vice President - Clinical Development (Age 43)
  • Abdel A. Fawzy Ph.D., Executive Vice President for Pharmaceutical and Supply Chain Development (Age 66)
  • Dominick M. Dipaolo, Senior Vice President - Quality and Regulatory Compliance (Age 41)
  • Raphael J. Mannino Ph.D., Chief Scientific Officer (Age 70)
  • Herbert J. Conrad, Chairman of the Board (Age 84)
  • Eric J. Ende M.D., Director (Age 48)
  • Adam K. Stern, Director (Age 53)

How do I buy Matinas BioPharma stock?

Shares of Matinas BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Matinas BioPharma's stock price today?

One share of Matinas BioPharma stock can currently be purchased for approximately $1.19.

How big of a company is Matinas BioPharma?

Matinas BioPharma has a market capitalization of $118.05 million.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.


MarketBeat Community Rating for Matinas BioPharma (MTNB)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Matinas BioPharma (NYSEAMERICAN:MTNB) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.67$7.67$7.67$7.67
Price Target Upside: 463.73% upside463.73% upside463.73% upside379.17% upside

Matinas BioPharma (NYSEAMERICAN:MTNB) Consensus Price Target History

Price Target History for Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma (NYSEAMERICAN:MTNB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
8/10/2017Roth CapitalSet Price TargetBuy$9.00View Rating Details
8/8/2017Maxim GroupSet Price TargetBuy$6.00View Rating Details
3/28/2017AegisReiterated RatingBuy -> Positive$8.00View Rating Details
(Data available from 1/19/2016 forward)

Earnings

Matinas BioPharma (NYSEAMERICAN:MTNB) Earnings History and Estimates Chart

Earnings by Quarter for Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma (NYSEAMERICAN MTNB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/2/2018N/AView Earnings Details
11/15/2017Q3 2017($0.05)($0.04)$0.05 million$0.05 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.05)($0.04)$0.02 million$0.05 millionViewListenView Earnings Details
5/16/2017Q1 2017($0.04)($0.25)$0.02 millionViewN/AView Earnings Details
4/3/2017Q4 2016($0.08)($0.03)ViewListenView Earnings Details
11/15/2016Q3 2016($0.11)ViewN/AView Earnings Details
8/15/2016Q2 2016($0.03)ViewN/AView Earnings Details
5/13/2016Q1 2016($0.04)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.03)ViewN/AView Earnings Details
11/10/2015Q3 2016($0.03)($0.11)$0.10 million$0.06 millionViewN/AView Earnings Details
8/13/2015Q2 2015($0.05)($0.04)$0.10 million$0.08 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.08)($0.07)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Matinas BioPharma (NYSEAMERICAN:MTNB) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Matinas BioPharma (NYSEAMERICAN:MTNB)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Matinas BioPharma (NYSEAMERICAN MTNB) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Matinas BioPharma (NYSEAMERICAN:MTNB)

Matinas BioPharma (NYSEAMERICAN MTNB) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/8/2017Adam K SternDirectorBuy100,000$1.38$138,000.00793,992View SEC Filing  
9/8/2017Roelof RongenCEOBuy5,000$1.36$6,800.003,539,416View SEC Filing  
9/7/2017James S ScibettaDirectorBuy5,000$1.29$6,450.00418,309View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Matinas BioPharma (NYSEAMERICAN MTNB) News Headlines

Source:
DateHeadline
Matinas BioPharma Holdings Inc (MTNB) Sees Large Decline in Short InterestMatinas BioPharma Holdings Inc (MTNB) Sees Large Decline in Short Interest
www.americanbankingnews.com - January 11 at 1:24 AM
Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered ... - GlobeNewswire (press release)Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered ... - GlobeNewswire (press release)
globenewswire.com - January 9 at 8:58 AM
Pre-Open Movers 01/08: (ALDR) (STX) (VUZI) Higher; (AXON) (GPRO) (APPN) Lower (more...)Pre-Open Movers 01/08: (ALDR) (STX) (VUZI) Higher; (AXON) (GPRO) (APPN) Lower (more...)
www.streetinsider.com - January 8 at 5:02 PM
ETF Preview: ETFs, Futures Lower Ahead of Speeches from Fed Officials, Consumer Credit DataETF Preview: ETFs, Futures Lower Ahead of Speeches from Fed Officials, Consumer Credit Data
www.nasdaq.com - January 8 at 10:09 AM
Matinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous CandidiasisMatinas BioPharma Achieves Statistical Endpoint for Success in Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
finance.yahoo.com - January 8 at 10:09 AM
Short Interest in Matinas BioPharma Holdings Inc (MTNB) Declines By 8.0%Short Interest in Matinas BioPharma Holdings Inc (MTNB) Declines By 8.0%
www.americanbankingnews.com - December 28 at 2:09 AM
Matinas BioPharma (MTNB) Appoints Matthew A. Wikler to Board - StreetInsider.comMatinas BioPharma (MTNB) Appoints Matthew A. Wikler to Board - StreetInsider.com
www.streetinsider.com - December 14 at 8:55 AM
Matinas BioPharma Holdings Inc (MTNB) Short Interest Down 6.2% in NovemberMatinas BioPharma Holdings Inc (MTNB) Short Interest Down 6.2% in November
www.americanbankingnews.com - December 12 at 2:26 AM
Short Interest in Matinas BioPharma Holdings Inc (MTNB) Drops By 2.8%Short Interest in Matinas BioPharma Holdings Inc (MTNB) Drops By 2.8%
www.americanbankingnews.com - November 27 at 9:30 PM
Matinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate UpdateMatinas BioPharma Reports 2017 Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 18 at 5:48 AM
Matinas BioPharma Holdings Inc (MTNB) Posts Quarterly  Earnings Results, Beats Expectations By $0.01 EPSMatinas BioPharma Holdings Inc (MTNB) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 17 at 8:21 PM

SEC Filings

Matinas BioPharma (NYSEAMERICAN:MTNB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Matinas BioPharma (NYSEAMERICAN MTNB) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.